Evidence map›Paper›PMID 40638023›Full record

Trial reportAnnals of nuclear medicine2025

Pharmacokinetics and dosimetry of [

Shoko Takano, Anri Inaki, Kenji Hirata, Richard B Sparks, Masahiko Sato, Satoshi Nomura, Toru Hattori, Hiroya Kambara, Quyen Nguyen, Tohru Shiga and 2 more

Abstract readClinical Trial, Phase II
PubMed Full text at PMC Publisher
In one paragraph

Trial report in Annals of nuclear medicine, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

12 authors.

Shoko TakanoDepartment of Radiation Oncology, Yokohama City University Graduate School of Medicine, 3-9 Fukuura, Kanazawa-ku, Yokohama, Kanagawa, 236-0004, Japan. tshoko@yokohama-cu.ac.jp.ORCID http://orcid.org/0000-0002-4289-6250
Anri InakiDivision of Functional Imaging, Exploratory Oncology Research and Clinical Trial Center (EPOC), National Cancer Center/Department of Nuclear Medicine, Kanazawa University, Kanazawa, Japan.
Kenji HirataDepartment of Diagnostic Imaging, Graduate School of Medicine, Hokkaido University, Hokkaido, Japan.
Richard B SparksCDE Dosimetry Services, Knoxville, TN, USA.
Masahiko SatoPK Sciences, Novartis Pharma K.K., Tokyo, Japan.
Satoshi NomuraBiostatistics Oncology, Novartis Pharma K.K., Tokyo, Japan.
Toru HattoriOncology Clinical Development, Novartis Pharma K.K., Tokyo, Japan.
Hiroya KambaraOncology Clinical Development, Novartis Pharma K.K., Tokyo, Japan.
Quyen NguyenPK Sciences Oncology, Novartis Pharma AG, Basel, Switzerland.
Tohru ShigaDepartment of Nuclear Medicine, Fukushima Medical University Hospital, Fukushima, Japan.
Seigo KinuyaDepartment of Nuclear Medicine, Kanazawa University Hospital, Kanazawa, Japan.
Makoto HosonoDepartment of Radiology, Kindai University, Osaka, Japan.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

objectiveThis prospective, open-label, single-arm, phase 2 study evaluated the efficacy, safety, pharmacokinetics (PK) and dosimetry of [

methodsThis is a PK/dosimetry analysis of [

resultsOf 35 patients included, 3 patients each had evaluable data for PK/dosimetry of [

conclusionThis is the first prospective Japanese study to demonstrate the use of [

trial registrationThis study is a prospective, open-label, multicenter, single-arm, phase 2 trial of [

Indexed as

DipeptidesGlutamate Carboxypeptidase IIHeterocyclic Compounds, 1-RingLutetiumProstatic Neoplasms, Castration-ResistantAgedAged, 80 and overAntigens, SurfaceEast Asian PeopleGallium IsotopesGallium RadioisotopesHumansJapanMaleMiddle AgedProspective StudiesAntigens, SurfaceDipeptidesFOLH1 protein, humangallium 68 PSMA-11Gallium IsotopesGallium RadioisotopesGlutamate Carboxypeptidase IIHeterocyclic Compounds, 1-RingLutetiumLutetium-177PluvictoProstate-Specific AntigenPSMA-11PSMA-617Radioisotopes[177Lu]Lu-PSMA-617[68Ga]Ga-PSMA-11DosimetryMetastatic castration-resistant prostate cancerPharmacokineticsRadiation exposure

Identifiers

PMID40638023
PMCPMC12559119

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.